

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company primarily focused on orphan and rare diseases. Among its major competitors, ChemoCentryx is ranked in 6th place for NPS while Biogen is 1st, and Accera is 2nd.Their current market cap is $3.71B